Skip to main content

Table 3 Utilization of drugs for OAD in MOC in comparison to Norway and Finland in 2010, in DDD/1000 inhabitants/day (DTID) and in percent of total use

From: Evaluation of pharmacotherapy of obstructive airway diseases in the Montenegrin outpatient care: comparison with two Scandinavian countries

Ord. No

MOC 2010

Norway 2010

Finland 2009

 

DTID (% of total use)

DTID (% of total use)

DTID (% of total use)

1.

Fenoterol, ipratropium 6.11 (33.6 %)

Salmeterol, corticosteroid 11.75 (18.4 %)

Formoterol and other drugs for OAD 10.86 (18.6 %)

2.

Salmeterol, fluticasone 3.41 (18.8 %)

Salbutamol 11.32 (17.7 %)

Salmeterol and other drugs for OAD 8.78 (15.0 %)

3.

Aminophylline 2.43 (13.4 %)

Ipratropium bromide 9.51 (14.9 %)

Salbutamol 8.10 (13.9 %)

4.

Fluticasone 1.98 (10.9 %)

Formoterol, corticosteroid 8.43 (13.2 %)

Fluticasone 5.49 (9.4 %)

5.

Salbutamol 1.89 (10.4 %)

Montelukast 4.70 (7.3 %)

Budesonide 5.39 (9.2 %)

6.

Salmeterol 1.45 (8.0 %)

Tiotropium bromide 4.36 (6.8 %)

Montelukast 5.16 (8.8 %)

7.

Beclomethasone 0.41 (2.2 %)

Fluticasone 3.11 (4.9 %)

Tiotropium bromide 3.50 (6.0 %)

8.

Theophylline 0.35 (1.9 %)

Terbutaline 2.94 (4.6 %)

Beclomethasone 3.27 (5.6 %)

9.

Budesonide 0.15 (0.8 %)

Budesonide 2.47 (3.9 %)

Terbutaline 2.05 (3.5 %)

10.

Othe 0.00 (0.0 %)

Other 5.38 (8.4 %)

Other 5.74 (9.8 %)

Total (R03)

18.18 (100.0 %)

63.97 (100.0 %)

58.34 (100.0 %)